(Q107283702)

35

object named as

Bettina E Hansen

0 references

Andrea K Boggild

8

object named as

Andrea K Boggild

0 references

author name string

Jordan J Feld

1

0 references

Christopher Kandel

2

0 references

Mia J Biondi

3

0 references

Robert A Kozak

4

0 references

Muhammad Atif Zahoor

5

0 references

Camille Lemieux

6

0 references

Sergio M Borgia

7

0 references

Jeff Powis

9

0 references

Janine McCready

10

0 references

Darrell H S Tan

11

0 references

Tiffany Chan

12

0 references

Bryan Coburn

13

0 references

Deepali Kumar

14

0 references

Atul Humar

15

0 references

Adrienne Chan

16

0 references

Braden O'Neil

17

0 references

Seham Noureldin

18

0 references

Joshua Booth

19

0 references

Rachel Hong

20

0 references

David Smookler

21

0 references

Wesam Aleyadeh

22

0 references

Anjali Patel

23

0 references

Bethany Barber

24

0 references

Julia Casey

25

0 references

Ryan Hiebert

26

0 references

Henna Mistry

27

0 references

Colin Hislop

29

0 references

Deanna M Santer

30

0 references

D Lorne Tyrrell

31

0 references

Jeffrey S Glenn

32

0 references

Adam J Gehring

33

0 references

Harry L A Janssen

The Lancet. Respiratory medicine

34

0 references

language of work or name

English

0 references

publication date

May 2021

0 references

published in

0 references

volume

9

0 references

issue

5

0 references

page(s)

498-510

0 references

cites work

Remdesivir for the Treatment of Covid-19 — Final Report

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Early administration of oral oseltamivir increases the benefits of influenza treatment

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

COVID-19 and emerging viral infections: The case for interferon lambda

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment.

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B).

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

SARS-CoV-2 viral load predicts COVID-19 mortality

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Predicting infectious SARS-CoV-2 from diagnostic samples

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Interferon Lambda: Modulating Immunity in Infectious Diseases

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Auto-antibodies against type I IFNs in patients with life-threatening COVID-19

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Interferon-stimulated gene expression in black and white hepatitis C patients during peginterferon alfa-2a combination therapy

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X

Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19

18 June 2021

1 reference

https://api.crossref.org/works/10.1016/S2213-2600(20)30566-X